Insilico Medicine and Eli Lilly Sign $2.75 Billion AI Drug Discovery Partnership

Milestone Partnership: One of Pharma's Largest AI Collaborations

On March 29, 2026, Insilico Medicine and Eli Lilly officially announced a strategic partnership agreement valued at up to $2.75 billion, with an upfront payment of $115 million. This collaboration is recognized by the industry as one of the largest AI-centric partnerships in the pharmaceutical industry to date, marking a new phase in the commercialization of generative AI in drug discovery.

This partnership builds on the long-term relationship between the two companies: a 2023 software licensing agreement and a 2025 research collaboration agreement laid the foundation for this large-scale strategic partnership.

Pharma.AI Platform: End-to-End AI Drug Discovery

Core Technology Components

Insilico Medicine's Pharma.AI platform is the technical core of this partnership, containing two key deep learning tools:

PandaOmics: Target Discovery Engine

PandaOmics is a multi-omics data-based target discovery platform capable of:

• Integrating multi-dimensional biological data including genomics, proteomics, and metabolomics
• Identifying novel therapeutic targets associated with specific diseases
• Predicting target druggability and safety risks
• Prioritizing the most promising research directions

Chemistry42: Molecular Design Engine

Chemistry42 is a generative AI molecular design platform capable of:

• De novo designing small molecule compounds with specific pharmacological activity
• Optimizing molecular ADMET properties (absorption, distribution, metabolism, excretion, toxicity)
• Predicting drug-induced liver injury (DILI) risk
• Designing protein binders for complex diseases

Collaboration Scope and Terms

Under the agreement terms:

• Lilly receives an exclusive global license to develop, manufacture, and commercialize a portfolio of preclinical oral therapeutics
• Both parties will collaborate on multiple R&D programs with targets selected by Lilly
• Insilico is eligible to receive tiered royalties on future product sales
• The remaining collaboration value (approximately $2.635 billion) is contingent on achieving specific development, regulatory, and commercial milestones

Rentosertib: The Frontier of AI Drug Discovery

From AI Design to Phase III Clinical Trials

Insilico Medicine's flagship candidate rentosertib (a TNIK inhibitor for idiopathic pulmonary fibrosis) represents one of the highest achievements in AI drug discovery.

In July 2026, rentosertib officially entered a Phase III registrational study, based on positive Phase IIa trial data. This makes rentosertib one of the most advanced end-to-end AI-discovered drug candidates globally.

Milestone Timeline

Industry Status of AI Drug Discovery

Rapid Expansion of Global Clinical Pipeline

In 2026, the global AI-originated clinical pipeline has expanded from approximately 24 programs in late 2023 to over 200 clinical-stage candidates. This growth reflects the rapid maturation of AI drug discovery technology and increased industry confidence.

Key Performance Metrics

Research data shows AI-discovered molecules performing well in clinical trials:

• Phase I trial success rate: 80-90%, significantly higher than historical industry averages
• Preclinical discovery time: Reduced by 30-40%, with candidate identification phase compressed to 13-18 months
• Phase II success rate: Close to historical averages (approximately 40%), indicating AI still has room for improvement in late-stage clinical challenges

Improved Regulatory Environment

In January 2026, the industry released "Guiding Principles of Good AI Practice in Drug Development," and the FDA continues to refine its framework for AI in regulatory decision-making. These regulatory developments provide a clearer pathway for the commercialization of AI drug discovery.

Asia-Pacific: The Fastest-Growing AI Drug Discovery Market

Market Size and Growth Projections

The Asia-Pacific region is recognized as the fastest-growing market for AI drug discovery globally, with a projected compound annual growth rate (CAGR) of 25-30%. Key driving factors include:

1. Government support: Governments in China, South Korea, India, and other countries actively promoting digital health initiatives
2. Rise of local platforms: Asia-Pacific native AI pharma platforms like Insilico Medicine, XtalPi, and METiS TechBio developing rapidly
3. Abundant clinical trial resources: Asia-Pacific has a large patient population and relatively lower clinical trial costs
4. Regulatory reform: Multiple Asia-Pacific countries establishing fast-track pathways for AI drug approvals

Major Asia-Pacific AI Pharma Platforms

Impact on Asia-Pacific Pharmaceutical Industry

The Insilico Medicine and Eli Lilly partnership has profound implications for the Asia-Pacific pharmaceutical industry:

1. Validation effect: Large-scale investment from a top global pharmaceutical company validates the commercial value of AI drug discovery
2. Talent attraction: High-value partnership funding will attract more top scientists and engineers to Asia-Pacific AI pharma
3. Ecosystem building: Driving AI upgrades in upstream and downstream companies (CROs, CMOs, data providers)
4. Regulatory demonstration: Providing reference cases for AI drug approval for Asia-Pacific regulatory authorities

Conclusion

The $2.75 billion partnership between Insilico Medicine and Eli Lilly marks an important turning point in AI drug discovery moving from technology validation to large-scale commercialization. With rentosertib entering Phase III clinical trials and the Pharma.AI platform being widely applied globally, AI-assisted drug discovery is reshaping the R&D paradigm of the pharmaceutical industry. For pharmaceutical companies and investors in the Asia-Pacific region, this trend presents both opportunities and challenges, requiring proactive positioning of AI capabilities to maintain competitive advantage.